United Therapeutics (NASDAQ:UTHR) Price Target Cut to $330.00 by Analysts at JPMorgan Chase & Co.

United Therapeutics (NASDAQ:UTHR - Free Report) had its target price reduced by JPMorgan Chase & Co. from $350.00 to $330.00 in a report released on Tuesday,Benzinga reports. They currently have an overweight rating on the biotechnology company's stock.

A number of other equities research analysts have also issued reports on UTHR. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley lifted their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Bank of America cut their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. UBS Group decreased their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Finally, HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $383.08.

United Therapeutics Trading Down 1.5%

Shares of NASDAQ:UTHR traded down $4.64 during midday trading on Tuesday, hitting $295.52. 300,699 shares of the stock were exchanged, compared to its average volume of 444,965. United Therapeutics has a twelve month low of $266.98 and a twelve month high of $417.82. The company has a 50 day moving average price of $301.04 and a 200-day moving average price of $320.31. The stock has a market cap of $13.33 billion, a P/E ratio of 11.79, a PEG ratio of 6.57 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same period last year, the firm posted $6.17 EPS. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. On average, equities research analysts expect that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $285.70, for a total value of $3,142,700.00. Following the sale, the executive vice president owned 36,781 shares of the company's stock, valued at $10,508,331.70. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 76,681 shares of company stock valued at $22,813,739 in the last quarter. Insiders own 10.30% of the company's stock.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Wealthfront Advisers LLC raised its holdings in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after buying an additional 18,313,424 shares during the period. Norges Bank acquired a new position in shares of United Therapeutics during the 4th quarter valued at $151,764,000. FMR LLC lifted its holdings in shares of United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after acquiring an additional 393,777 shares in the last quarter. Vaughan Nelson Investment Management L.P. purchased a new stake in United Therapeutics during the 1st quarter worth $101,354,000. Finally, Nuveen LLC purchased a new position in United Therapeutics in the first quarter valued at about $83,533,000. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.